|
|
Factsheet as on August 31, 2025 |
Factsheet as on August 31, 2025
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Sailesh Raj Bhan, Divya Dutt Sharma, Lokesh Maru
Exit Load
Within 1 Month - 1%
Fund Size
Rs 8,357 crs
Launch Date
June 05, 2004
Investment Objective
To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.
Market Cap Allocation
Scheme Performance
| 1 Year | 2 Years | 3 Years | 5 Years | |
| Scheme (%) | -2.07 | 21.16 | 22.52 | 19.01 |
| Nifty 500 (%) | -5.37 | 15.23 | 13.59 | 19.12 |
Top 10 Holdings
| Company Name | % of Assets |
| Sun Pharmaceutical Industries Ltd. | 11.9 |
| Divi Laboratories Ltd. | 7.3 |
| Cipla Ltd. | 6.1 |
| Lupin Ltd. | 6.1 |
| Apollo Hospitals Enterprise Ltd. | 5.9 |
| Dr Reddys Laboratories Ltd. | 5.9 |
| Medplus Health Services Ltd. | 3.7 |
| Vijaya Diagnostic Centre Ltd. | 3.5 |
| Glaxo Smithkline Pharmaceuticals Ltd. | 3.0 |
| Gland Pharma Ltd. | 3.0 |
Year On Year Performance (Scheme V/S Nifty 500)
Ratios:
| Standard Deviation | 14.84 |
| Information Ratio | 0.17 |
| Beta | 0.78 |
| Sharpe Ratio | 0.26 |
Top 10 Sectoral Holdings (%)
SIP Returns
Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390